相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience
Vera Espirito Santo et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1
Edwin Jousma et al.
PEDIATRIC BLOOD & CANCER (2015)
Selumetinib for the treatment of cancer
Kristen Keon Ciombor et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
Brian Weiss et al.
NEURO-ONCOLOGY (2015)
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Nancy Ratner et al.
NATURE REVIEWS CANCER (2015)
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas
Brigitte C. Widemann et al.
NEURO-ONCOLOGY (2014)
Sirolimus for Non-Progressive NF1-Associated Plexiform Neurofibromas: An NF Clinical Trials Consortium Phase II Study
Brian Weiss et al.
PEDIATRIC BLOOD & CANCER (2014)
Phase II Trial of Pirfenidone in Children and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
Brigitte C. Widemann et al.
PEDIATRIC BLOOD & CANCER (2014)
Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas
Camille Hua et al.
PEDIATRICS (2014)
Optimizing biologically targeted clinical trials for neurofibromatosis
David H. Gutmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
S. V. Holt et al.
BRITISH JOURNAL OF CANCER (2012)
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A. Robertson et al.
LANCET ONCOLOGY (2012)
Atypical Neurofibromas in Neurofibromatosis Type 1 are Premalignant Tumors
Eline Beert et al.
GENES CHROMOSOMES & CANCER (2011)
Neurofibromatosis type 1
Kevin P. Boyd et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
